Key PointsBristol Myers Squibb plans to acquire Karuna Therapeutics for $14 billion. The company also expanded its psychiatric and neurological portfolio.It also offered$4.1 billion for cancer drug start-up RayzeBio.5 stocks we like better than Bristol-Myers SquibbBristol Myers Squibb Company NYSE: BMY is on a buying spree, announcing two acquisitions in less than a week. On December 22, the pharma giant said it was acquiring Karuna Therapeutics Inc. NASDAQ: KRTX for $330 per share in cash, for a total equ ...